May Health Announces Data From Feasibility Studies of its Novel Ovarian Rebalancing™ Treatment and Receives Approval From FDA for Pivotal Trial

Research presented at the European Society of Human Reproduction and Embryology (ESHRE) meeting demonstrated the early safety and effectiveness results of the company's investigational treatment for ovulation induction

Related Keywords

Paris ,France General ,France ,Copenhagen ,Køavn ,Denmark ,Anne Morrissey ,Antoine Papiernik ,Saad Amer ,Linkedin ,University Of Nottingham ,European Society Of Human Reproduction ,Drug Administration ,European Society ,Human Reproduction ,Ovarian Rebalancing ,Reproductive Medicine ,May Health ,Managing Partner ,New Concepts ,Polycystic Ovary Syndrome ,Sofinnova Partners ,Hopkins Medicine ,